Shots: The P-III POSEIDON trial evaluates Imfinzi (1500mg, q3w, FD, for 4 cycles) + Pt-based CT or Imfinzi + Tremelimumab + CT vs CT alone in 1013 patients with mNSCLC […]readmore
Tags : Stage IV
Shots: The P-III DANUBE study involves assessing Imfinzi as monothx. & Imfinzi + Tremelimumab vs SOC CT as a 1L treatment for patients with unresectable, Stage IV (metastatic) UC whose […]readmore
Shots: The P-III POSEIDON study involves assessing of Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment in patients with non-squamous […]readmore
Shots: The P-III NEPTUNE study involves assessing of Imfinzi + tremelimumab vs SOC platinum-based CT as a 1L treatment in patients with Stage IV metastatic NSCLC + high tumor mutational […]readmore
Shots: Boehringer Ingelheim (BI) and Amal Therapeutics enter into a clinical research agreement to conduct P-Ib KISIMA-01 study assessing Amal’s ATP128 and BI’s BI754091 with microsatellite stable (MSS) patients with […]readmore